If you search for HArmonyCa—Allergan Aesthetics dual-effect injectable combining hyaluronic acid (HA) and calcium hydroxylapatite (CaHA)—you will encounter conflicting information. Some US medical spa websites claim the product is "FDA approved," while Google search results display official-looking US Food and Drug Administration (FDA) database links. Furthermore, social media feeds highlight its widespread availability across Europe, Latin America, and its official launch in Canada in May 2026.
The definitive, regulatory-verified answer is: No. HArmonyCa Lidocaine is not FDA-approved in the United States as of August 24, 2026.
A comprehensive audit of the FDA Premarket Approval (PMA) database across all 1,046 Class III dermal filler entries (product code LMH) confirms zero records for HArmonyCa, HarmonyCa, or any Allergan/AbbVie hybrid HA-CaHA formulation. The FDA links that appear in search engines are post-market adverse event reports from the global MAUDE complaint database—not marketing authorizations or safety clearances.
This page covers composition versus Radiesse, why MAUDE pages are not approvals, which ClinicalTrials.gov records actually exist (including a China Phase 3 that is easy to misread as a US study), partial reversibility, and why gray-market syringes are not a US workaround.
Direct Summary: HArmonyCa US Status at a Glance
| Feature / Question | Clinical & Regulatory Fact |
|---|---|
| Product Name | HArmonyCa Lidocaine (Allergan Aesthetics / AbbVie) |
| Product Category | Hybrid Dermal Filler & Biostimulator (Dual-Action Injectable) |
| Composition | ~70% v/v cross-linked Hyaluronic Acid (20 mg/mL) + ~30% Calcium Hydroxylapatite (CaHA) microspheres (25–45 µm; ~55.7% w/w) + 0.3% Lidocaine HCl |
| Carrier Gel | Cross-linked Hyaluronic Acid gel (No Carboxymethylcellulose / CMC) |
| US FDA Approval Status | NOT FDA-Approved (0 PMA records under product code LMH) |
| Why Do FDA Pages Exist? | FDA MAUDE database entries (adverse event reports from global use), which do not represent approval |
| Largest active registry trial | NCT07032597 — China Phase 3 vs Restylane Perlane Lidocaine; 252 enrolled; Active, not recruiting. Not a US-sited trial. |
| Completed ex-US Phase 3 | NCT05452070 — Canada, Spain, UK; n=171; completed May 8, 2025 |
| International status | CE-marked in Europe (2022); Health Canada authorization with a May 25–26, 2026 commercial launch |
| Reversibility | Partially Reversible: Hyaluronidase dissolves the 70% HA gel matrix; CaHA microspheres are not dissolved by hyaluronidase |
| Approved US Alternatives | Pure CaHA: Radiesse (Merz, PMA P050052); Pure HA: Juvéderm (P110033) & Restylane (P020023); PLLA: Sculptra (P030050) |
Is HArmonyCa FDA-Approved in the United States?
In the United States, injectable dermal fillers intended for aesthetic facial augmentation are classified by the FDA as Class III Medical Devices under regulation 21 CFR 878.3540 (product code LMH). Class III devices carry the highest level of regulatory scrutiny and cannot be cleared through a simple 510(k) premarket notification. Instead, they require a full Premarket Approval (PMA) application demonstrating reasonable assurance of safety and effectiveness through rigorous, prospective clinical trials.
FDA Premarket Approval (PMA) Verification:
Total LMH Dermal Filler PMA Records Audited: 1,046
Search Queries: "HArmonyCa", "HarmonyCa", "Harmony CA", "Allergan Hybrid"
Matching Dermal Filler PMA Approvals Found: 0
Every legal dermal filler marketed in the US—such as Juvéderm Voluma (P110033), Restylane Lyft (P020023), Radiesse (P050052), and Sculptra (P030050)—holds an active PMA number with published Summary of Safety and Effectiveness Data (SSED).
As of August 24, 2026, HArmonyCa has no approved PMA application, no approved PMA supplement, and no humanitarian device exemption. Any US clinic or medical spa claiming that HArmonyCa is "FDA approved" is misrepresenting the regulatory record.
Why Does Google Show FDA MAUDE Pages for HArmonyCa?
A major source of patient and injector confusion is that entering "HArmonyCa FDA" into search engines frequently returns results hosted directly on accessdata.fda.gov. Clicking these links brings up official FDA pages under product code LMH (such as MDR Report Key 19409878).
To understand why these exist, it is necessary to understand the purpose of the MAUDE (Manufacturer and User Facility Device Experience) database.
How MAUDE Differs from FDA Approval:
┌───────────────────────────────────────────────┬───────────────────────────────────────────────┐
│ FDA PMA Approval (e.g., SSED Database) │ FDA MAUDE Database │
├───────────────────────────────────────────────┼───────────────────────────────────────────────┤
│ • Formal regulatory authorization to market │ • Post-market voluntary/mandatory complaint │
│ and sell a medical device in the US. │ repository for adverse clinical events. │
│ • Requires audited clinical trial data. │ • Contains reports from global use regardless │
│ • Proves safety and efficacy standards. │ of whether the device is cleared in the US. │
│ • Generates a public Approval Letter. │ • A MAUDE page is evidence of a complication, │
│ │ NOT evidence of FDA endorsement. │
└───────────────────────────────────────────────┴───────────────────────────────────────────────┘
The Mechanism of Global Adverse Event Logging
Medical device manufacturers headquartered or operating in the United States (such as AbbVie/Allergan) are legally required under federal post-market surveillance regulations (21 CFR Part 803) to log significant adverse events and product complaints reported anywhere in the world.
When a patient in the United Kingdom, France, Brazil, or Canada experiences an adverse event (such as localized vascular compromise, nodule formation, or sterile abscess) involving HArmonyCa manufactured at Allergan Pringy facility in France, Allergan must submit a Medical Device Report (MDR) to the FDA MAUDE system.
The presence of an MDR detail page on an FDA server is simply a record that a patient somewhere in the world reported a side effect. It is not an approval, not a clearance, and not a validation of clinical safety.
What Is HArmonyCa and How Does It Differ from Radiesse and HA Fillers?
To evaluate HArmonyCa, one must examine its rheology, particle chemistry, and biological mechanism of action relative to established US injectable classes.
Formulation Comparison:
┌───────────────────────────────┬───────────────────────────────┬───────────────────────────────┐
│ Pure HA Filler (e.g. Juvéderm)│ Radiesse (Merz) │ HArmonyCa (Allergan) │
├───────────────────────────────┼───────────────────────────────┼───────────────────────────────┤
│ • 100% Cross-linked HA │ • 30% CaHA Microspheres │ • ~30% CaHA Microspheres │
│ • No biostimulatory mineral │ • 70% Aqueous Carboxymethyl- │ • ~70% Cross-linked HA Gel │
│ microspheres │ cellulose (CMC) Gel Carrier │ • NO Carboxymethylcellulose │
│ • Immediate volume & water │ • Carrier resorbs in 8–12 wks │ • Immediate HA structural lift│
│ binding │ • Pure CaHA neocollagenesis │ + sustained CaHA collagen │
│ • 100% Hyaluronidase-soluble │ • NOT Hyaluronidase-soluble │ • PARTIALLY Hyaluronidase-sol │
└───────────────────────────────┴───────────────────────────────┴───────────────────────────────┘
1. The Chemical Composition of HArmonyCa
According to published structural and material characterization studies (such as PMC11853979 and PMC11412701), HArmonyCa Lidocaine is formulated as an integrated dual-phase suspension:
- Hyaluronic Acid Component: Cross-linked sodium hyaluronate gel at a concentration of 20 mg/mL (comprising approximately 70% of the total syringe volume). This provides immediate mechanical tissue projection, hydration, and viscoelastic lift.
- Calcium Hydroxylapatite Component: Smooth, spherical Calcium Hydroxylapatite (CaHA) microspheres ranging from 25 to 45 micrometers (µm) in diameter (constituting approximately 30% by volume and 55.7% by weight of the formulation). These microspheres act as a biological scaffold, stimulating host fibroblast activation and long-term Type I and Type III neocollagenesis.
- Anesthetic: 0.3% Lidocaine Hydrochloride for patient comfort during subdermal injection.
2. How HArmonyCa Differs Chemically from Radiesse
Patients familiar with biostimulators often ask if HArmonyCa is "just Radiesse with filler." The key difference lies in the carrier matrix:
- Radiesse (Merz Aesthetics, PMA P050052): Formulated with 30% CaHA microspheres suspended in a 70% aqueous gel composed of Carboxymethylcellulose (CMC), water, and glycerin. CMC is an inert, non-cross-linked polysaccharide that provides temporary volume for 8 to 12 weeks before being completely metabolized via endogenous macrophage enzymatic breakdown, leaving the CaHA microspheres behind to stimulate collagen. Radiesse contains zero hyaluronic acid. For details on how pure CaHA operates against PLLA, see our comparative guide on Sculptra vs Radiesse.
- HArmonyCa: Completely eliminates the temporary CMC carrier. Instead, CaHA microspheres are directly embedded within a cohesive, cross-linked hyaluronic acid matrix. This allows the carrier itself to provide sustained structural volume, elasticity, and dermal hydration over 6 to 12 months while the CaHA particles induce concurrent extracellular matrix remodeling.
What Is NCT07032597 — and Is It a US Registration Trial?
A live ClinicalTrials.gov record is not a US PMA. It is also not automatically a US-sited study.
NCT07032597 is a Phase 3, randomized, evaluator-blinded comparison of HArmonyCa Lidocaine versus Restylane Perlane Lidocaine (US trade name Restylane Lyft, PMA P020023 family) for mid-face volume. As retrieved August 24, 2026:
- Status: Active, not recruiting
- Enrollment: 252 actual
- Start: May 26, 2025; estimated completion October 2026
- Primary outcome: MFVDS responder status at month 6
- Listed locations: nine sites, all in China (Beijing, Wuhan, Nanjing, Wuxi, Shanghai, Hangzhou)
- Oversight flags on the public record: not marked FDA-regulated device, not marked US export
There was no US-sited HArmonyCa registration trial on ClinicalTrials.gov in this check. Treating NCT07032597 as “the US pivotal” is the error this page exists to prevent.
Completed records that also are not US approvals:
- NCT05452070: international Phase 3, n=171, completed May 8, 2025, sites in Canada, Spain, and the United Kingdom
- NCT05119777: Phase 4 open-label post-marketing study, n=140, completed September 15, 2023, sites in France (interventional, not a passive registry)
A trial can later support a PMA, including with foreign data, but completion ≠ submission ≠ approval. No public SSED exists until FDA approves a PMA. Do not use an estimated 2026 completion date as a 2026 US launch date.
Is HArmonyCa Reversible with Hyaluronidase?
One of the most vital safety considerations for any injectable is reversibility. If a patient experiences an acute vascular occlusion (intra-arterial injection leading to tissue ischemia) or develops an asymmetrical, displeasing aesthetic result, can the product be dissolved?
With pure hyaluronic acid fillers (such as Juvéderm or Restylane), clinicians inject the enzyme hyaluronidase, which hydrolyzes the beta-1,4-linkages of hyaluronic acid within hours, completely restoring native tissue anatomy. For an overview of filler categories, see our guide on biostimulators vs HA fillers.
With HArmonyCa, reversibility is strictly partial and hybrid-dependent:
Enzymatic Dissolution Dynamics in HArmonyCa:
[HArmonyCa Syringe (70% HA + 30% CaHA)]
│
+ Hyaluronidase
│
▼
┌───────────────────────────────────┬───────────────────────────────────┐
│ Hyaluronic Acid Fraction (~70%) │ CaHA Microspheres (~30%) │
│ • Rapidly hydrolyzed and dissolved│ • Completely IMMUNE to hyalase │
│ • Relieves acute vascular pressure│ • Remain embedded in tissue │
│ • Eliminates water-bound volume │ • Must metabolize naturally │
└───────────────────────────────────┴───────────────────────────────────┘
Vascular occlusion is a filler emergency. This page does not publish a dose or pulse protocol. Hyaluronidase is the usual first-line enzyme for the HA fraction; it does not dissolve CaHA microspheres. Hybrid emboli are therefore more complex than pure-HA gels. Aesthetic lumps can shrink when the HA gel is dissolved; remaining CaHA and new collagen still have to remodel over months. Published complication papers on this hybrid (PMC11853979) emphasize hyaluronidase plus supportive care — they are not a substitute for an on-site reversal kit and a clinician who knows the product is only partly reversible.
Where Is HArmonyCa Actually Authorized (Europe, UK, Canada)?
Authorization geography is not a US PMA.
- Europe / UK: CE Mark in 2022 after Allergan’s acquisition of the original developer, Luminera. Used in clinics in those markets for soft-tissue augmentation, often described in the literature along the lateral mid-face. Country-count marketing (“available in N countries”) is not reproduced here.
- Canada: Allergan Aesthetics announced a commercial launch on May 25–26, 2026 after Health Canada licensing. Canadian launch copy is easy to misread as US news. Crossing a border for an injection still leaves complication management on the wrong side of that border. This page is not a travel itinerary.
- United States: not PMA-approved. NCT07032597 is a China Phase 3, not a US site list.
The Gray Market Danger: Why Unapproved US Injections Are Dangerous
Because HArmonyCa carries substantial global brand awareness, an illicit "gray market" has emerged in the United States. Some non-compliant medical spas, online compounding distributors, and unlicensed injectors import unapproved syringes of HArmonyCa from overseas pharmacies or Canadian brokers to offer "exclusive European treatments" to American clients.
Patients must understand the severe medical, legal, and financial hazards associated with unapproved injectable imports:
Risks of Gray-Market / Unapproved Injectable Imports:
┌────────────────────────────────────────────────────────────────────────┐
│ 1. Complete Loss of Cold-Chain Integrity: │
│ Cross-linked hyaluronic acid and suspended microspheres degrade if │
│ exposed to uncontrolled cargo temperatures during unmonitored │
│ international transit, altering extrusion force and elasticity. │
├────────────────────────────────────────────────────────────────────────┤
│ 2. Counterfeiting & Unsterile Formulations: │
│ High-demand unapproved injectables are prime targets for counterfeit│
│ manufacturing operations, carrying risks of bacterial contamination,│
│ biofilm infection, and chronic foreign-body granulomas. │
├────────────────────────────────────────────────────────────────────────┤
│ 3. Zero Manufacturer or Legal Safety Recourse: │
│ If a vascular occlusion, tissue necrosis, or severe inflammatory │
│ reaction occurs from an illegally imported syringe, Allergan │
│ Aesthetics cannot support the case, malpractice insurance may deny │
│ coverage for the injector, and the patient has no regulatory relief.│
└────────────────────────────────────────────────────────────────────────┘
Commercial importation and administration of an unapproved Class III aesthetic filler is not a legal US practice loophole. A US clinic that cannot produce a PMA number is not offering an “exclusive European protocol”; it is offering an unapproved device. The only lawful US administration path in the public record would be a registered US trial site with IRB consent — and this review did not find one.
Approved US Alternatives: What Can You Get Legally Today?
Patients seeking the specific clinical benefits of HArmonyCa—immediate structural lift combined with sustained collagen biostimulation—have excellent, fully FDA-approved options available in US dermatology and plastic surgery practices today.
FDA-Approved Treatment Pathways:
┌────────────────────────────────────────────────────────────────────────┐
│ Goal: Pure Biostimulation & Firming │
│ ──> Radiesse (PMA P050052): Pure CaHA microspheres in CMC carrier. │
│ Can be injected at full strength for structural jawline lift or in │
│ hyperdilute protocols for neck and cheek tightening. │
├────────────────────────────────────────────────────────────────────────┤
│ Goal: Immediate Volume & Deep Mid-Face Projection │
│ ──> Juvéderm Voluma (PMA P110033) or Restylane Lyft (PMA P020023): │
│ High-elasticity pure hyaluronic acid gels with 100% reversibility. │
├────────────────────────────────────────────────────────────────────────┤
│ Goal: Global Neocollagenesis for Facial Wasting │
│ ──> Sculptra (PMA P030050): Poly-L-lactic acid (PLLA) microparticles │
│ stimulating gradual, multi-month collagen regeneration. │
├────────────────────────────────────────────────────────────────────────┤
│ Goal: Intradermal Micro-Hydration & Texture Smoothing │
│ ──> Skinvive by Juvéderm (PMA P110033/S059 & S099): Microdroplet HA │
│ for superficial cheek and neck smoothness. │
└────────────────────────────────────────────────────────────────────────┘
US clinicians who want both structure and biostimulation already layer approved products (for example, a high-G-prime HA for projection and hyperdilute Radiesse or Sculptra for skin quality). That is not evidence that layering “beats” HArmonyCa; it is the legal toolkit while this hybrid remains unapproved. See Juvéderm vs Restylane and the Skinvive neck indication for on-label HA options.
What to Ask If a US Clinic Claims HArmonyCa Is FDA-Approved
If you encounter a US medical spa or aesthetic provider advertising HArmonyCa treatments, protect your safety by asking these precise questions:
- "Can you provide the FDA Premarket Approval (PMA) number for HArmonyCa?"
Why to ask: They will not be able to produce one. Legitimate US fillers have verifiable PMA numbers (e.g., P110033, P050052). - "Are you a listed US site on an IRB-approved HArmonyCa protocol — and can you show the NCT number and consent form?"
Why to ask: NCT07032597’s public site list is in China. A US clinic citing that NCT as local authorization is misreading the registry. - "Where was this syringe purchased and how was cold-chain transit documented?"
Why to ask: If the product was imported through secondary international channels, it violates federal supply-chain regulations and poses severe contamination risks. - "If I want biostimulation and volume today, can we design an FDA-approved protocol using Radiesse, Sculptra, or high-G-prime HA fillers?"
Why to ask: Connects your aesthetic goals to safe, legally approved products backed by domestic clinical support and established emergency reversal protocols.
Sources
- FDA Premarket Approval (PMA) Database, Class III Dermal Fillers (Product Code LMH, 21 CFR 878.3540): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P020023
- FDA Medical Device Reporting (MAUDE) Database, MDR Detail Report (Product Code LMH, HArmonyCa Lidocaine Global Surveillance Record): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=19409878&pc=LMH
- ClinicalTrials.gov NCT07032597, HArmonyCa Lidocaine vs Restylane Perlane Lidocaine for mid-face volume (China sites; Active, not recruiting; n=252): https://clinicaltrials.gov/study/NCT07032597
- ClinicalTrials.gov NCT05452070, international Phase 3 HArmonyCa Lidocaine (Canada, Spain, UK; n=171; completed May 8, 2025): https://clinicaltrials.gov/study/NCT05452070
- ClinicalTrials.gov NCT05119777, Phase 4 open-label HArmonyCa mid-face study (France; n=140; completed September 15, 2023): https://clinicaltrials.gov/study/NCT05119777
- PMC11853979, hybrid HA-CaHA composition (~70% v/v HA, ~30% CaHA, 20 mg/mL, 25–45 µm, 0.3% lidocaine, no CMC) and complication management: https://pmc.ncbi.nlm.nih.gov/articles/PMC11853979/
- PMC11412701, hybrid injectable review (20 mg/mL HA, CaHA 25–45 µm, 55.7% w/w, 0.3% lidocaine): https://pmc.ncbi.nlm.nih.gov/articles/PMC11412701/
- Allergan Aesthetics / PR Newswire, HArmonyCa Lidocaine Canada launch, May 25, 2026: https://www.prnewswire.com/news-releases/allergan-aesthetics-launches-harmonyca-lidocaine-in-canada-302581891.html
- FDA-approved dermal fillers index: https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/fda-approved-dermal-fillers
